In this free webinar, attendees will gain insights into how next-generation multiplex immunoassays address cross-reactivity, ensuring consistent high performance across any panel size. Attendees will learn how to design a study that leverages disease-focused protein panels, large-scale biobank data and integrated power calculators for robust insights. The featured speakers will discuss how to optimize data analysis with intuitive and transparent software, seamlessly integrated with annotation layers, a publication explorer for proteins of interest and powerful statistical tools. The speakers will also share what is possible with examples of high-impact published research showcasing biomarker discovery and validation.
TORONTO, March 19, 2025 /PRNewswire-PRWeb/ -- Protein signatures provide critical insights into underlying biological mechanisms and play a pivotal role in identifying actionable biomarkers. The ability to measure multiple proteins simultaneously offers a more comprehensive view of biology, enabling deeper insights into disease complexity and more robust stratification of groups based on biomarkers. Technologies that support multiplex protein profiling are essential for efficiently identifying meaningful protein signatures and driving translational research.
However, achieving reliable protein measurements in multiplex requires overcoming key analytical challenges, including assay cross-reactivity, specificity and sensitivity. The ideal technology should deliver high precision without compromising assay performance, regardless of panel size. Additionally, researchers must navigate the complexities of selecting proteins that accurately represent key pathways, managing technically demanding workflows and applying advanced statistical methods to analyze and interpret larger datasets.
Success in protein profiling depends not only on selecting the right assays or an appropriate panel size for the research question but also on a well-designed study, a streamlined workflow and a robust yet user-friendly statistical pipeline for data analysis and interpretation. These factors directly influence the speed of data generation, the quality of insights and the overall impact of the results.
In this webinar, attendees will learn how the integration of a compact, simple benchtop instrument powered by next-generation technology provides access to a complete protein profiling solution: From research question and study design to data analysis and interpretation.
Through real-world published examples, attendees will explore how this solution accelerates biomarker discovery and validation in neurology, oncology, cardiovascular diseases and immune-mediated diseases, with applications in patient stratification and clinical research.
Register for this webinar today to explore how next-generation protein profiling technology is accelerating biomarker discovery and validation.
Join experts from Olink Proteomics, part of Thermo Fisher Scientific, Shana Lamers, MS, MBA, Senior Field Application Scientist; and Elisa Viering, Software Product Manager, for the live webinar on Thursday, April 3, 2025, at 9am EDT (3pm CEST/EU-Central).
For more information, or to register for this event, visit A Complete Solution for Identifying Protein Signatures: From Sample to Actionable Results.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article